Coronary heart disease (CHD) is the leading cause of death in the United States. CHD risk differs between genders, with coronary events lagging behind ten years for women in comparison to men. Low-density lipoprotein cholesterol lowering with statin therapy is a major target for cardiovascular risk reduction. The benefit of statin therapy has been well established in men, for both primary and secondary prevention. However, the same has not been shown for women. While studies have demonstrated benefit in women for secondary prevention, their role in primary prevention of cardiovascular disease remains controversial. Data released over the past several years regarding statin efficacy and safety in men and women has been inconsistent, given that these studies had small sample sizes with numerous study limitations. A recent large scale meta-analysis of both primary and secondary statin prevention trials with sex-specific outcomes demonstrated a similar benefit in both men and women. Statins demonstrated a decrease in cardiovascular events and all-cause mortality in both sexes. In regards to statin safety, additional trials investigating the difference in adverse events of statins in men versus women, particularly new onset of diabetes, myalgias, and liver dysfunction, are warranted. Increased awareness and monitoring of female patients for myalgias and hyperglycemia should be considered as a precaution. Overall, women need to be better represented in prospective clinical trials powered to evaluate gender-specific differences in statin safety and efficacy in the management of cardiovascular disease.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update. Circulation. 2015;131:e29–e222. highlights importance of risk reduction in statin therapy.
Lloyd-Jones DM, Larson MG, Beiser A, Levy D. Lifetime risk of developing coronary heart disease. Lancet. 1999;353(9147):89.
Yusuf S, Reddy, Ounpuu S, Anand S. Global burden of cardiovascular disease: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746–53.
Kappert K, Bohm M, Schmeider R, et al. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET). Circulation. 2012;126(8):934.
Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 American College of Cardiology/American Heart Association cholesterol guideline. Ann Intern Med. 2014;160:339–343.
Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomized trials. Lancet. 2015;385:1397–405. this meta-analysis supports our conclusion of a similar benefit in both men and women in both primary and secondary statin prevention trials.
Dale KM, Coleman CI, Shah SA, et al. Impact of gender on statin efficacy. Curr Med Res Opin. 2007;23:565–74.
Mombelli G, Bosisio R, Calabresi L, et al. Gender-related lipid and/or lipoprotein responses to statins in subjects in primary and secondary prevention. J Clin Lipidol. 2015;9:226–33.
Sakabe K, Fukuda N, Fukuda Y, Wakayama K, Nada T, Morishita S, et al. Gender differences in short-term effects of atorvastatin on lipid profile, fibrinolytic parameters, and endothelial function. Nutr Metab Cardiovasc Dis. 2008;18(3):182–8.
Nishi K, Uno M, Fukuzawa K, Horiguchi H, Shinno K, Nagahiro S. Clinicopathological significance of lipid peroxidation in carotid plaques. Atherosclerosis. 2002;160:289–96.
Nakajima K. Sex-related differences in response of plasma lipids to simvastatin: the Saitama Postmenopausal Lipid Intervention Study. S-POLIS Group. Clin Ther. 1999;21(12):2047–57.
Bukkapatnam R, Gabler NB, Lewis WR. Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis. Prev Cardiol. 2010;13:84–90.
Petretta M, Costanzo P, Perrone-Filardi P, Chiariello M. Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis. Int J Cardiol. 2010;138(1):25–31.
Gutierrez J, Ramirez G, Rundek T, et al. Statin therapy in the prevention of recurrent cardiovascular events. Arch Intern Med. 2012;172(12):909–19.
Kostis WJ, Cheng JQ, Dobrzynski JM, et al. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59(6):572–82.
Bushnell CD, Griffin J, Newby LK, Goldstein LB, Mahaffey KW, Graffagnino CA, et al. Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke. 2006;37(6):1427–31.
Heart Protection Study Collaborative Group. Effects of cholesterol lowering with simvastatin on stroke and other major vascular event sin 20536 people with cerebrovascular disease or other high-risk conditions. Lancet. 2004;363:757–67.
Plehn JF, Davis BR, Sacks FM, Rouleau JL, Pfeffer MA, Bernstein V, et al. Reduction of stroke incidence after myocardial infarction with pravastatin. The Cholesterol And Recurrent Events (CARE) study. Circulation. 1999;99:216–23.
The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57.
Goldstein LB, Amarenco P, Lamonte M, Gilbert S, Messig M, Callahan A, et al. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke. 2008;39(9):2444–8.
Mosca L. Sex, statins, and statistics. Lancet. 2015;385:1368–9.
Pencina MJ, Navar-Boggan A, D’Agostino RB, et al. Application of new cholesterol guidelines to a population-based sample. N Engl J Med. 2014;370:1422–31. Highlights adult eligiblility for statin therapy.
Conflict of Interest
The authors declare that they have no competing interests.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
This article is part of the Topical Collection on Statin Drugs
About this article
Cite this article
Plakogiannis, R., Arif, S.A. Women Versus Men: Is There Equal Benefit and Safety from Statins?. Curr Atheroscler Rep 18, 6 (2016). https://doi.org/10.1007/s11883-016-0562-9
- HMG-CoA reductase inhibitors
- Lipid profile
- Cardiovascular disease